Quarterly ResultMay 6, 2026, 08:07 AM
UroGen Q1 ZUSDURI Revenue +109% to $29.2M; Total Revenue +152%
AI Summary
UroGen Pharma reported strong first-quarter 2026 financial results, with ZUSDURI™ revenue more than doubling quarter-over-quarter to $29.2 million, driven by broader utilization following the permanent J Code. Total revenue increased by 152% year-over-year to $51.0 million, while the net loss significantly narrowed to $23.6 million. The company also highlighted continued advancement of its pipeline, including UGN-103 on track for NDA submission and UGN-501 IND submission, and expanded its debt facility by $200 million.
Key Highlights
- ZUSDURI revenue reached $29.2 million in Q1 2026, a 109% quarter-over-quarter growth.
- JELMYTO generated $21.7 million in revenue in Q1 2026, a 7% year-over-year growth.
- Total revenue for Q1 2026 was $51.0 million, a 152% increase from Q1 2025.
- Net loss for Q1 2026 was $23.6 million, or ($0.47) per share, compared to $43.8 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $140.3 million as of March 31, 2026.
- Expanded debt facility with Pharmakon Advisors for $200 million, with an option for an additional $50 million.
- UGN-103 NDA submission for LG-IR-NMIBC is on track for the second half of 2026.
- UGN-501 IND submission for high-grade NMIBC is planned for Q2 2026, with Phase 1 trial by year-end.
- Reaffirmed 2026 JELMYTO revenue guidance of $97 million to $101 million.
- Reaffirmed 2026 operating expense guidance of $240 million to $250 million.
Price Impact
More from URGN